{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:36:05Z","timestamp":1746185765725,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02291-2","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T09:03:35Z","timestamp":1663405415000},"page":"5229-5243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase\u00a03 CENTURION Trial"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct03670810","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jiying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guogang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiying","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-088X","authenticated-orcid":false,"given":"Shengyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"2291_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631\u201349.","journal-title":"Neurol Clin"},{"key":"2291_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-019-1048-2","volume":"20","author":"C Yao","year":"2019","unstructured":"Yao C, Wang Y, Wang L, et al. Burden of headache disorders in China, 1990\u20132017: findings from the Global Burden of Disease Study 2017. J Headache Pain. 2019;20:102.","journal-title":"J Headache Pain"},{"key":"2291_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/pme.12277","volume":"15","author":"N Luo","year":"2014","unstructured":"Luo N, Qi W, Zhuang C, et al. A satisfaction survey of current medicines used for migraine therapy in China: is Chinese patent medicine effective compared with Western medicine for the acute treatment of migraine? Pain Med. 2014;15:320\u20138.","journal-title":"Pain Med"},{"key":"2291_CR4","doi-asserted-by":"crossref","unstructured":"Zhao H, Zhang L, Ford J, et al. Treatment patterns and real-world outcomes among patients with episodic migraine in China: results from the Chinese Adelphi Disease Specific Programme. ISPOR Annual Meeting 2021, PND64. https:\/\/www.ispor.org\/conferences-education\/conferences\/past-conferences\/ispor-2021\/program\/posters. Accessed 30 Mar 2022.","DOI":"10.1016\/j.jval.2021.04.848"},{"key":"2291_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s13311-017-0592-1","volume":"15","author":"JJY Ong","year":"2018","unstructured":"Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action [published correction appears in Neurotherapeutics. 2018 Jan 8]. Neurotherapeutics. 2018;15:274\u201390.","journal-title":"Neurotherapeutics"},{"key":"2291_CR6","unstructured":"MAXALT (rizatriptan benzoate) tablets, for oral use highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020864s011s016s017s018s019,020865s012s016s018s020s021lbl.pdf. Accessed 10 Mar 2022."},{"issue":"Pt 1","key":"2291_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/123.1.9","volume":"123","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P, Saxena PR, Dahl\u00f6f C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123(Pt 1):9\u201318.","journal-title":"Brain"},{"key":"2291_CR8","unstructured":"DURLAZA (aspirin) Extended-Release Capsules, for oral use highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/200671s000lbl.pdf. Accessed 3 Feb 2022."},{"key":"2291_CR9","unstructured":"FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory. Accessed 16 Feb 2022."},{"key":"2291_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/head.12154","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53:1300\u201311.","journal-title":"Headache"},{"key":"2291_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s11606-014-3107-3","volume":"30","author":"JN Mafi","year":"2015","unstructured":"Mafi JN, Edwards ST, Pedersen NP, Davis RB, McCarthy EP, Landon BE. Trends in the ambulatory management of headache: analysis of NAMCS and NHAMCS data 1999\u20132010. J Gen Intern Med. 2015;30:548\u201355.","journal-title":"J Gen Intern Med"},{"key":"2291_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Zhang Y, Yao Y, Cao H. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain. 2020;21:53.","journal-title":"J Headache Pain"},{"key":"2291_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","volume":"21","author":"DB Clemow","year":"2020","unstructured":"Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action\u2014review of a selective 5-HT1F agonist. J Headache Pain. 2020;21:71.","journal-title":"J Headache Pain"},{"key":"2291_CR14","unstructured":"REYVOW (lasmiditan) tablets, for oral use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211280s000lbl.pdf Accessed 3 Nov 2021."},{"key":"2291_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"M F\u00e4rkkil\u00e4","year":"2012","unstructured":"F\u00e4rkkil\u00e4 M, Diener HC, G\u00e9raud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11:405\u201313.","journal-title":"Lancet Neurol"},{"key":"2291_CR16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase\u00a03 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894\u2013904.","journal-title":"Brain"},{"key":"2291_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0333102419855080","volume":"39","author":"JH Krege","year":"2019","unstructured":"Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from phase\u00a03 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN [published correction appears in Cephalalgia. 2021; 41:1035. Cephalalgia. 2019;39:957\u201366.","journal-title":"Cephalalgia"},{"key":"2291_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia. 2021;41:294\u2013304.","journal-title":"Cephalalgia"},{"key":"2291_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-021-01343-2","volume":"22","author":"C Tassorelli","year":"2021","unstructured":"Tassorelli C, Bragg S, Krege J, et al. Safety findings from CENTURION, a phase\u00a03 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain. 2021;22:132.","journal-title":"J Headache Pain"},{"key":"2291_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0333102420905307","volume":"40","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Marcus SC, Shewale AR, Dodick DW, Viswanathan HN, Doshi JA. Acute treatment patterns in patients with migraine newly initiating a triptan. Cephalalgia. 2020;40:437\u201347.","journal-title":"Cephalalgia"},{"key":"2291_CR21","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49\u201373 (Erratum in Circulation. 2014;129:S74\u20135).","journal-title":"Circulation"},{"key":"2291_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/head.13544","volume":"59","author":"SK Tepper","year":"2019","unstructured":"Tepper SK, Krege J, Lombard L, et al. Characterization of dizziness after lasmiditan: findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache. 2019;59:1052\u201362.","journal-title":"Headache"},{"key":"2291_CR23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","volume":"59","author":"SJ Tepper","year":"2002","unstructured":"Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B\/1D receptor agonists. Arch Neurol. 2002;59:1084\u20138.","journal-title":"Arch Neurol"},{"key":"2291_CR24","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1212\/WNL.0b013e3181a71220","volume":"72","author":"ME Bigal","year":"2009","unstructured":"Bigal ME, Kurth T, Hu H, et al. Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology. 2009;72:1864\u201371.","journal-title":"Neurology"},{"key":"2291_CR25","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB, et al. Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health. 2020;11:2150132720963680.","journal-title":"J Prim Care Community Health"},{"key":"2291_CR26","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","volume":"358","author":"MD Ferrari","year":"2001","unstructured":"Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin, 5-HT1B\/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668\u201375.","journal-title":"Lancet"},{"key":"2291_CR27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjp.0702773","volume":"128","author":"T Nilsson","year":"1999","unstructured":"Nilsson T, Longmore J, Shaw D, et al. Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol. 1999;128:1133\u201340.","journal-title":"Br J Pharmacol"},{"key":"2291_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.nurt.2010.03.003","volume":"7","author":"L Neeb","year":"2010","unstructured":"Neeb L, Meents J, Reuter U. 5-HT1F receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics. 2010;7:176\u201382.","journal-title":"Neurotherapeutics"},{"key":"2291_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltr\u00e1n","year":"2018","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Villalon CM, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88\u201397.","journal-title":"Pharmacol Ther"},{"key":"2291_CR30","unstructured":"Depomed Inc. CAMBIA (diclofenac potassium), for oral solution. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022165lbl.pdf. Accessed 3 Nov 2021."},{"key":"2291_CR31","first-page":"131","volume":"4","author":"E Yoon","year":"2016","unstructured":"Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;4:131\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"2291_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bja\/aen094","volume":"100","author":"KT Pattinson","year":"2008","unstructured":"Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100:747\u201358.","journal-title":"Br J Anaesth"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02291-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:49:51Z","timestamp":1664552991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02291-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2291"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02291-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}